Johnson & Johnson vs. Minerva Neurosciences, Inc
Johnson & Johnson (JNJ) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| JNJ | NERV | |
|---|---|---|
| Market Cap | $614.36 billion | $188.22 million |
| Revenue (TTM) | $97.93 billion | — |
| Net Income (TTM) | $21.04 billion | $-415,074,589 |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | NERV | |
|---|---|---|
| P/E Ratio | 29.88 | — |
| Price / Book | 7.23 | -0.74 |
| Price / Sales | 6.27 | — |
NERV leads on 1 of 1 valuation factors.
Profitability
| JNJ | NERV | |
|---|---|---|
| Net Margin | 21.48% | — |
| Return on Equity | 24.76% | 163.41% |
NERV leads on 1 of 1 profitability factors.
Dividend
| JNJ | NERV | |
|---|---|---|
| Dividend Yield | 2.08% | — |
| Payout Ratio | 62.18 | — |
JNJ and NERV split the dividend factors evenly.
Risk & Sentiment
| JNJ | NERV | |
|---|---|---|
| Short Interest | 0.67% | 3.60% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, NERV overview, NERV financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.